Trulicity Patient Assistance for Low-Income: How to Get Dulaglutide at Reduced or No Cost

Why Trulicity Costs $931 Without a Plan

Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist manufactured exclusively by Eli Lilly. Because no biosimilar competitor exists yet, Lilly retains full pricing power. The wholesale acquisition cost (WAC) for the 1.5 mg/0.5 mL single-dose pen sits near $931 per month as of early 2026.

That figure represents the pharmacy's list price before any rebates, discount cards, or insurance adjudication. A 2023 analysis in Diabetes Care found that out-of-pocket spending on GLP-1 receptor agonists averaged $150 to $300 per month even among insured patients, depending on plan design and formulary tier. For uninsured patients, the full cash price applies unless a patient assistance pathway intervenes.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D beneficiaries (effective January 2025) helps seniors, but does not apply to commercially insured or uninsured adults under 65. Those populations remain exposed to the full retail cost unless they access one of the programs described below.

Lilly Cares Foundation: The Primary No-Cost Program

The Lilly Cares Foundation Patient Assistance Program (PAP) is the single most impactful resource for low-income patients who need Trulicity. It provides the medication at zero cost, shipped directly to the prescribing physician's office.

Eligibility criteria are straightforward. Applicants must be U.S. residents, lack prescription drug coverage that covers Trulicity (or face a coverage gap), and have a household income at or below 400% of the federal poverty level. For 2026, that threshold equals $62,400 for a single-person household and $129,600 for a family of four.

The application process requires the prescriber to complete a medical certification form and the patient to provide proof of income (tax return, pay stubs, or a signed attestation). Lilly Cares reviews applications within 4 to 6 weeks. Once approved, patients receive 90-day supplies shipped to their doctor's office for pickup. Requalification happens annually.

A key limitation: Lilly Cares does not cover patients who have any form of prescription coverage that includes GLP-1 agents, even if the copay is unaffordable. Patients in Medicare Part D plans with high cost-sharing must use the Part D Extra Help program or the $2,000 cap rather than Lilly Cares.

The Trulicity Savings Card for Commercially Insured Patients

Patients with commercial insurance (employer-sponsored or ACA marketplace plans) who do not qualify for Lilly Cares may still reduce their copay through the Trulicity Savings Card. This manufacturer coupon applies at the pharmacy counter and can bring the patient's monthly cost to $25 for up to 24 months of use.

Eligibility requirements include active commercial prescription coverage that already includes Trulicity on its formulary. The card cannot be used by patients enrolled in any federal healthcare program (Medicare, Medicaid, Tricare, VA). Maximum annual benefit caps apply, typically between $6,000 and $9 to 000 in manufacturer-paid assistance per year.

Activation is simple. Patients download the card from Lilly's website, present it at their pharmacy alongside their insurance card, and the discount applies automatically during adjudication. If the pharmacy's system rejects the card, a call to the number on the back usually resolves processing issues within minutes.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, noted in a 2024 ADA policy statement: "Cost-related non-adherence to GLP-1 receptor agonists remains one of the most significant barriers to achieving glycemic targets in type 2 diabetes. Manufacturer programs help, but systemic coverage reforms are necessary to close remaining gaps" (ADA Standards of Care, 2024).

Medicare Part D and the $2,000 Out-of-Pocket Cap

For patients aged 65 and older (or those under 65 with qualifying disabilities), Medicare Part D now includes a hard $2,000 annual out-of-pocket maximum as of January 2025 under the Inflation Reduction Act. This means that even if Trulicity sits on a high-cost Tier 4 formulary position, total yearly spending by the beneficiary cannot exceed $2,000 across all covered medications.

Before reaching that cap, most Part D plans charge 25% to 33% coinsurance for Tier 3 or Tier 4 drugs. On a $931 monthly price, that translates to roughly $233 to $307 per fill until the cap is reached (typically by month 7 to 9 of the year).

Patients earning below 150% FPL ($23,400 for a single individual in 2026) may qualify for Medicare Extra Help (Low-Income Subsidy), which reduces Part D premiums to zero and caps copays at $4.50 for generics and $11.20 for brand-name drugs per fill. Applications go through the Social Security Administration or state Medicaid offices.

A 2022 study in the Journal of the American Medical Association found that among Medicare beneficiaries prescribed GLP-1 agonists, 18.3% reported cost-related non-adherence prior to the cap's implementation. Early 2025 data suggest this rate has dropped substantially, though peer-reviewed confirmation is pending.

State Pharmaceutical Assistance Programs (SPAPs)

Twenty-eight states operate their own pharmaceutical assistance programs that supplement federal coverage or fill gaps for uninsured residents. These programs vary widely in eligibility, formulary inclusion, and benefit design.

Notable examples for GLP-1 coverage include New York's EPIC program (income limit $75,000 single, $100,000 married), New Jersey's PAAD program (income limit $37,581 single), and Pennsylvania's PACE program (income limit $33,500 single). Each maintains its own formulary; patients should verify that dulaglutide is covered before applying.

For patients in states without an SPAP, or those above income thresholds, 340B-eligible health centers offer another pathway. Federally Qualified Health Centers (FQHCs) purchase outpatient drugs at 340B-discounted prices (typically 25% to 50% below WAC) and may pass savings to uninsured patients through sliding-fee schedules. The Health Resources and Services Administration maintains a directory of 340B-covered entities searchable by ZIP code.

Navigating Prior Authorization Successfully

Most commercial and Medicare plans require prior authorization (PA) before covering Trulicity. The PA process confirms medical necessity and typically requires documentation that the patient has type 2 diabetes, has tried or has a contraindication to metformin, and meets A1c or clinical criteria specified by the plan.

A 2021 survey published in Annals of Internal Medicine found that 93% of prior authorization requests for GLP-1 receptor agonists were eventually approved, but 34% required at least one appeal. The median time from submission to final approval was 11 days.

Steps to improve PA success rates:

1. Document metformin trial (or intolerance) clearly in the chart
2. Include the most recent A1c value (plans typically require A1c above 7.0% despite therapy)
3. Note cardiovascular risk factors, as dulaglutide carries a cardiovascular outcome benefit from the REWIND trial (HR 0.88 for MACE, 95% CI 0.79-0.99, N=9,901)
4. Submit peer-to-peer review requests promptly if initially denied

The REWIND trial result is particularly useful in PA appeals because it establishes dulaglutide as medically necessary beyond glycemic control alone. Plans with step-therapy requirements sometimes waive them when cardiovascular indication is documented.

Comparing Dulaglutide Access to Other GLP-1 Options

Patients who cannot access Trulicity through any of the above programs may consider alternative GLP-1 receptor agonists with different assistance landscapes.

Semaglutide (Ozempic) carries a similar cash price (~$935/month) but Novo Nordisk operates its own PAP (NovoCare) with comparable 400% FPL income limits. Liraglutide (Victoza) also falls under NovoCare. Exenatide extended-release (Bydureon BCise) by AstraZeneca has a lower WAC (~$750/month) and the AZ Access 360 program covers uninsured patients below 400% FPL.

The 2024 ADA Standards of Care recommend choosing GLP-1 agents based on clinical profile first (cardiovascular benefit, weight loss efficacy, renal outcomes) and then identifying the most accessible option within the chosen clinical profile. "Clinicians should actively assist patients in identifying affordability programs rather than defaulting to less effective therapies solely on cost grounds," the guideline states.

For patients whose primary goal is weight management rather than glycemic control, dulaglutide is FDA-approved only for type 2 diabetes. Semaglutide 2.4 mg (Wegovy) carries the obesity indication. This distinction matters for insurance coverage, as plans may deny Trulicity for weight management while covering Wegovy under a separate obesity benefit.

The Compounding Question: Why Dulaglutide Is Different

Unlike semaglutide, which became widely available through compounding pharmacies during the 2022-2024 shortage period, dulaglutide has not appeared on the FDA Drug Shortage Database in a manner that would trigger 503A/503B compounding eligibility. As of May 2026, no legal compounded dulaglutide product exists in the U.S. market.

Patients who encounter offers for "compounded dulaglutide" online should treat these with extreme caution. The FDA has issued multiple warnings about unapproved GLP-1 products sold through telehealth platforms that lack proper 503B outsourcing facility registration.

This absence of a compounded alternative makes the PAP and savings card pathways especially important for dulaglutide compared to the semaglutide market, where compounded options (when legally available during shortage periods) provide a lower-cost tier.

Step-by-Step: Applying for Lilly Cares

The application process involves coordination between patient and prescriber. Here is the sequence:

The patient gathers income documentation: most recent federal tax return (Form 1040), two consecutive pay stubs, or (if no income) a signed self-attestation form provided in the application packet.

The prescriber completes the medical portion, including diagnosis (ICD-10 code E11.x for type 2 diabetes), prescribed dose, and a statement that the medication is medically necessary.

Both sections are submitted together via fax (1-800-545-6962) or through the Lilly Cares online portal. Incomplete applications are the most common reason for delays. Double-checking that all signature lines are filled and income documentation matches the stated household size prevents most rejections.

Upon approval, the first shipment arrives at the prescriber's office within 2 to 3 weeks. Patients pick up their supply during a regular office visit or scheduled pickup window. Refills ship automatically every 90 days until annual requalification is due.

If denied, patients receive a written explanation. The most common denial reason is having existing prescription coverage (even with high copays). In this situation, patients should explore whether their plan offers a formulary exception or tier reduction. A 2023 analysis in Health Affairs found that 41% of formulary exception requests for diabetes medications were granted when supported by physician documentation of medical necessity and prior therapy failure.

What to Do This Week

Patients currently paying full price or skipping doses due to cost should take three concrete steps immediately. First, check income against the 400% FPL threshold ($62,400 single, $129,600 family of four) to determine Lilly Cares eligibility. Second, call the prescriber's office to request they initiate the PAP application, as the medical certification cannot be completed without physician involvement. Third, for commercially insured patients above the income threshold, activate the Trulicity Savings Card online and present it at the next pharmacy fill to verify the $25 copay applies. The Lilly customer support line for all access programs is 1-800-545-6962, available Monday through Friday, 8 AM to 8 PM Eastern.